BPC-157 + TB-500 + Thymosin α-1 + GHK-Cu

The four-compound expansion of the BPC-157 + TB-500 classic adds two complementary arms:

1. Thymosin alpha-1 contributes immune-modulation — supporting T-cell function during physical stress / recovery, particularly relevant to people with immune dysregulation as a contributor to slow healing.
2. GHK-Cu contributes copper-binding tissue-regeneration support, with strongest evidence in topical / wound-bed contexts but increasing interest in systemic use for connective-tissue and collagen support.

The combination logic is to address recovery as a multi-system process: tissue protection, cell migration, immune support, and ECM remodeling. The trade-off is straightforward — more arms increase the theoretical scope of effect but also reduce per-compound research depth and expand the interaction surface.

The peer-reviewed literature on this combination is summarized below across two tiers — controlled human research (the highest standard) and preclinical / animal-model evidence.

• Does the four-compound combination produce meaningfully better functional recovery than the two-compound version?
• Is the systemic GHK-Cu arm doing biological work distinct from topical use?
• What are the long-term implications of chronic immune modulation via thymosin alpha-1 in healthy adults?

The four-compound comprehensive recovery stack is the natural extension of the BPC-157 + TB-500 classic and reflects the user-community pattern of layering compounds for broader effect. The honest framing is that broader does not necessarily mean better — each additional compound brings additional source-quality, tolerability, and interaction-surface concerns, while combination-specific evidence remains absent. For most readers exploring this space, the simpler two-compound version is a more defensible starting point, with thymosin alpha-1 or GHK-Cu added only when there's a specific rationale beyond generic stacking.